Neuropathic pain is underdiagnosed and poorly assessed

Millions of people suffer from neuropathic pain, such as diabetic peripheral neuropathy, which severely impacts quality of life and healthcare costs. Diagnosis today relies on subjective scales and non-specific exams, delaying treatment and complicating clinical research.

Noxisense brings objectivity to pain assessment

Our technology combines controlled nerve stimulation with brain response recording to quantify the condition of pain-carrying small fibers. It delivers objective, reproducible data that supports earlier diagnosis, precise patient follow-up, and reliable outcomes in clinical trials.

Objective vs. subjective pain scales

Fast and non-invasive

Comparable data across time and patients

Supports therapy decisions & drug development

Science-backed innovation with protected IP

The Nx-1 device has been tested in pilot studies in Argentina, Germany, and Belgium, benchmarked against gold-standard nerve stimulation methods such as laser. We are advancing toward clinical trials in diabetic neuropathy and exploring applications in fibromyalgia.

Our technology is patent-protected with national phases active in Argentina, Europe, and the United States.